We are live on !
Find out more
BVF Inc Portfolio holdings
AUM
$3.04B
Turnover
10.42%
1-Year Est. Return
129.63%
This Fund
S&P 500
This Quarter Est. Return
-17.58%
1 Year Est. Return
+129.63%
3 Year Est. Return
+531.24%
5 Year Est. Return
+1,335.11%
10 Year Est. Return
+16,856.28%
AUM
$495M
AUM Growth
-$71.6M
(-13%)
Cap. Flow
+$24.8M
Cap. Flow % of AUM
Cap. Flow %
5.02%
Top 10 Holdings %
Top 10 Hldgs %
75.58%
Holding
34
New
4
Increased
11
Reduced
4
Closed
7
Avg Time Held
1.2
years
Top 10 Avg Time Held
1.2
years
Top 20 Avg Time Held
1.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ironwood Pharmaceuticals
IRWD
|
+$30.1M |
| 2 |
CASC
Cascadian Therapeutics
CASC
|
+$22.6M |
| 3 |
CTIC
CTI BioPharma
CTIC
|
+$17.3M |
| 4 |
VTAE
Vitae Pharmaceuticals
VTAE
|
+$8.2M |
| 5 |
Viracta Therapeutics
VIRX
|
+$4.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Exelixis
EXEL
|
+$10.4M |
| 2 |
SGEN
Seagen
SGEN
|
+$9.7M |
| 3 |
FPRX
Five Prime Therapeutics
FPRX
|
+$5.98M |
| 4 |
CNCE
Concert Pharmaceuticals
CNCE
|
+$4.53M |
| 5 |
Astria Therapeutics
ATXS
|
+$2.75M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.19% |
| 2 | Miscellaneous | 12.81% |
Similar funds
BVF Inc's Q3 2015 Portfolio in Review
As of Q3 2015, BVF Inc held 34 positions worth $495M, down 13% from $567M the previous quarter. Its ten largest holdings account for 76% of the portfolio.
BVF Inc deployed $24.8M of net new capital in Q3 2015, opening 4 new positions and adding to 11 existing holdings. Its largest new stake was CTI BioPharma: 1,000,000 shares worth $14.6M.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 89% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Concert Pharmaceuticals, an estimated $4.53M trimmed.
- BVF Inc's largest Q3 2015 buy was CTI BioPharma: 1,000,000 shares worth $14.6M.
- BVF Inc added most to Ironwood Pharmaceuticals in Q3 2015, an estimated $30.1M increase.
- BVF Inc's biggest Q3 2015 reduction was Concert Pharmaceuticals, cutting an estimated $4.53M.
- BVF Inc fully exited Exelixis in Q3 2015, selling an estimated $10.4M.
- BVF Inc's ten largest holdings make up 76% of its $495M portfolio in Q3 2015.
- BVF Inc opened 4 new positions and closed 7 in Q3 2015.
- BVF Inc's portfolio value fell 13% quarter-over-quarter to $495M.
Based on BVF Inc's 13F filing for Q3 2015, filed 16 Nov 2015.